1-4 of 4
Melissa R. Junttila
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Wassim Abida, Andrew W. Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R. Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Christopher J. Logothetis, Michael J. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1111–1120.
https://doi.org/10.1158/1078-0432.CCR-23-3508
Published: 15 March 2024
View article titled, Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Open the PDF for Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide in another window
Includes: Supplementary data
Journal Articles

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Anneleen Daemen, Jonathan E. Cooper, Szymon Myrta, Matthew J. Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora Modrusan, Jarrod R. Tremayne, Cecile C. de la Cruz, Mark Merchant, Scott E. Martin, Yibing Yan, Melissa R. Junttila
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (4): 1162–1173.
https://doi.org/10.1158/1078-0432.CCR-20-1835
Published: 15 February 2021
View article titled, Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Open the PDF for Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody

Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh, Teemu T. Junttila
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6447–6458.
https://doi.org/10.1158/1078-0432.CCR-18-1139
Published: 13 December 2018
View article titled, IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
Open the PDF for IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody in another window
Includes: Supplementary data
Journal Articles

Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment

Johannes Riegler, Yassin Labyed, Stephen Rosenzweig, Vincent Javinal, Alessandra Castiglioni, Claudia X. Dominguez, Jason E. Long, Qingling Li, Wendy Sandoval, Melissa R. Junttila, Shannon J. Turley, Jill Schartner, Richard A.D. Carano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4455–4467.
https://doi.org/10.1158/1078-0432.CCR-17-3262
Published: 14 September 2018
View article titled, Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment
Open the PDF for Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment in another window
Includes: Supplementary data